An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

John M. Burke, Andrei Shustov, James Essell, Dipti Patel-Donnelly, Jay Yang, Robert Chen, Wei Ye, Wen Shi, Sarit Assouline, Jeff Sharman

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences